Core Insights - Eli Lilly is set to produce its next-generation experimental weight-loss pill, orforglipron, at a new multi-billion-dollar manufacturing facility in Texas [1] Company Developments - The new manufacturing plant will be dedicated to the production of orforglipron, indicating a significant investment in expanding the company's capabilities in the weight-loss medication market [1]

Industry Trend - GLP-1s were expected to eliminate weight-loss retreats, but instead are revitalizing them [1]

Regulatory Strategy - Novo plans to seek US regulatory approval for a high-dose version of its blockbuster weight-loss shot Wegovy [1]